<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="strains and their evolving subclades during the seasons substantially influences" exact="influenza" post="vaccine effectiveness (IVE). In order to further substantiate the"/>
 <result pre="virus characterization for IVE estimates during the seasons, we performed" exact="influenza" post="virus type and subtype specific IVE estimates. IVE estimates"/>
 <result pre="of the intraseasonal changes of the heterogeneous mix of circulating" exact="influenza" post="virus strains for three influenza seasons (2016/17 to 2018/19)"/>
 <result pre="the heterogeneous mix of circulating influenza virus strains for three" exact="influenza" post="seasons (2016/17 to 2018/19) in Austria. Adjusted overall IVE"/>
 <result pre="dynamic of the ever changing genetic pattern of the circulating" exact="influenza" post="viruses and their influence on IVE estimates. This emphasizes"/>
 <result pre="importance of detailed genetic virus surveillance for reliable IVE estimates." exact="influenza" post="vaccine effectiveness influenza genetic heterogeneity influenza virus genetic variability"/>
 <result pre="genetic virus surveillance for reliable IVE estimates. influenza vaccine effectiveness" exact="influenza" post="genetic heterogeneity influenza virus genetic variability and vaccine effectiveness"/>
 <result pre="for reliable IVE estimates. influenza vaccine effectiveness influenza genetic heterogeneity" exact="influenza" post="virus genetic variability and vaccine effectiveness influenza antigenic drift"/>
 <result pre="influenza genetic heterogeneity influenza virus genetic variability and vaccine effectiveness" exact="influenza" post="antigenic drift and influenza vaccine effectiveness fig-count: table-count: equation-count:"/>
 <result pre="virus genetic variability and vaccine effectiveness influenza antigenic drift and" exact="influenza" post="vaccine effectiveness fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction"/>
 <result pre="effectiveness fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Each year," exact="influenza" post="epidemics infect about 5–10% of adults and 10–20% of"/>
 <result pre="and in the elderly. The most effective way to prevent" exact="influenza" post="virus infection and associated complications is by vaccination (2,"/>
 <result pre="infection and associated complications is by vaccination (2, 3). Unfortunately," exact="influenza" post="viruses continually change over time through genetic and antigenic"/>
 <result pre="virus neutralization by immune response. Therefore, the composition of the" exact="influenza" post="vaccines has to be reconsidered annually and if required,"/>
 <result pre="update and revaccination, the ability of the vaccine to prevent" exact="influenza" post="virus infection in the general population varies each year"/>
 <result pre="the general population varies each year (2). Immunity generated by" exact="influenza" post="vaccines is a complex issue and is not only"/>
 <result pre="vaccinee's individual immunological history like number and type of previous" exact="influenza" post="virus infections and/or previous influenza virus vaccinations. In addition,"/>
 <result pre="number and type of previous influenza virus infections and/or previous" exact="influenza" post="virus vaccinations. In addition, waning of vaccine-induced immunity during"/>
 <result pre="season is also described as a contributing factor causing suboptimal" exact="influenza" post="vaccine effectiveness (IVE) (5), whereby the decrease of influenza"/>
 <result pre="suboptimal influenza vaccine effectiveness (IVE) (5), whereby the decrease of" exact="influenza" post="virus vaccine specific antibodies as test variable was used"/>
 <result pre="variable. The influence of changes in the dynamics of circulating" exact="influenza" post="virus types/subtypes during the season and especially of their"/>
 <result pre="virus characterization during the season for IVE estimates, we performed" exact="influenza" post="virus type and subtype specific IVE estimates overall and"/>
 <result pre="of the intraseasonal changes of the heterogeneous mix of circulating" exact="influenza" post="virus strains for three influenza seasons (2016/17 to 2018/19)"/>
 <result pre="the heterogeneous mix of circulating influenza virus strains for three" exact="influenza" post="seasons (2016/17 to 2018/19) in Austria. Materials and Methods"/>
 <result pre="Sentinel Influenza Surveillance System and Samples Tested Sentinel surveillance for" exact="influenza" post="viruses was performed as described previously (6). Briefly, annual"/>
 <result pre="influenza viruses was performed as described previously (6). Briefly, annual" exact="influenza" post="virus surveillance is performed from October (calendar week 40)"/>
 <result pre="Austria (DINOE), who collect nasopharyngeal swabs from patients presenting with" exact="influenza" post="like illness as defined by the ECDC (7). The"/>
 <result pre="specimen collection is provided with the sample (6). Vaccination Available" exact="influenza" post="vaccines for the season 2016/17 in Austria were: TIV"/>
 <result pre="vaccine strains: A(H3N2): A/Hong Kong/4801/2014-like virus, A(H1N1)pdm09: A/California/7/2009-like virus and" exact="influenza" post="B: B/Brisbane/60/2008-like virus (Victoria lineage), the LAIV included additionally"/>
 <result pre="strains were A(H3N2): A/Hong Kong/4801/2014-like virus, A(H1N1)pdm09: A/Michigan/45/2015-like virus and" exact="influenza" post="B: B/Brisbane/60/2008-like virus (Victoria lineage). During the season 2017/18"/>
 <result pre="B/Brisbane/60/2008-like virus (Victoria lineage). During the season 2017/18 quadrivalent inactivated" exact="influenza" post="vaccines (QIV) were available in Austria for the first"/>
 <result pre="between calendar weeks 40 to 48 and the non-adjuvanted, inactivated" exact="influenza" post="vaccines were primarily used. People above 65 years of"/>
 <result pre="as previously described (6). Briefly, sentinel specimens were tested for" exact="influenza" post="viruses by reverse transcription realtime PCR (RT realtime PCR)."/>
 <result pre="Estimation of Influenza Vaccine Effectiveness Overall IVE against laboratory confirmed" exact="influenza" post="virus infections were estimated as described previously (6) by"/>
 <result pre="design where a case is defined as a patient with" exact="influenza" post="as confirmed by RT-PCR and a control as a"/>
 <result pre="RT-PCR and a control as a patient tested negative for" exact="influenza" post="virus. Odds ratios (OR) for medically attended, laboratory-confirmed influenza"/>
 <result pre="for influenza virus. Odds ratios (OR) for medically attended, laboratory-confirmed" exact="influenza" post="were estimated by multivariate logistic regression adjusting for gender,"/>
 <result pre="season. A prerequisite for the IVE calculation was the epidemic" exact="influenza" post="virus activity, as indicated by a rate of influenza"/>
 <result pre="epidemic influenza virus activity, as indicated by a rate of" exact="influenza" post="positive samples of ≥50%. In addition overall and type/subtype"/>
 <result pre="2018/19 As can be seen in Figure 1, the three" exact="influenza" post="seasons in Austria differed significantly with regard to the"/>
 <result pre="types and subtypes and with regard to the intensity of" exact="influenza" post="virus activity. Figure 1 Columns: number of influenza virus"/>
 <result pre="intensity of influenza virus activity. Figure 1 Columns: number of" exact="influenza" post="virus detections per week and per type/subtype during the"/>
 <result pre="influenza virus detections per week and per type/subtype during the" exact="influenza" post="seasons 2016/17 to 2018/19; pie chart: proportion (%) of"/>
 <result pre="2016/17 to 2018/19; pie chart: proportion (%) of the circulating" exact="influenza" post="virus types/subtypes during the respective influenza seasons. The season"/>
 <result pre="(%) of the circulating influenza virus types/subtypes during the respective" exact="influenza" post="seasons. The season 2016/17 was a moderate influenza season"/>
 <result pre="the respective influenza seasons. The season 2016/17 was a moderate" exact="influenza" post="season with an influenza incidence of 270,000 cases in"/>
 <result pre="The season 2016/17 was a moderate influenza season with an" exact="influenza" post="incidence of 270,000 cases in Austria and was characterized"/>
 <result pre="Austria and was characterized by the nearly exclusive circulation of" exact="influenza" post="A(H3N2) viruses. The season 2017/18 was dominated by influenza"/>
 <result pre="of influenza A(H3N2) viruses. The season 2017/18 was dominated by" exact="influenza" post="B viruses and with co-circulation of A(H1N1)pdm09 viruses. Influenza"/>
 <result pre="detectable in a minority of samples. Despite the dominance of" exact="influenza" post="B viruses, season 2017/18 was a very severe influenza"/>
 <result pre="of influenza B viruses, season 2017/18 was a very severe" exact="influenza" post="season with an incidence of 440,000 influenza cases in"/>
 <result pre="a very severe influenza season with an incidence of 440,000" exact="influenza" post="cases in Austria. In the following season 2018/19, again,"/>
 <result pre="was dominated by A(H1N1)pdm09 viruses with co-circulating A(H3N2) viruses. The" exact="influenza" post="incidence was 145,000 influenza cases in Austria, and it"/>
 <result pre="viruses with co-circulating A(H3N2) viruses. The influenza incidence was 145,000" exact="influenza" post="cases in Austria, and it was therefore a moderate"/>
 <result pre="influenza cases in Austria, and it was therefore a moderate" exact="influenza" post="season. Detailed information on the epidemiologic characteristics of the"/>
 <result pre="season. Detailed information on the epidemiologic characteristics of the three" exact="influenza" post="seasons (the number of samples tested, number of influenza"/>
 <result pre="three influenza seasons (the number of samples tested, number of" exact="influenza" post="viruses detected and detailed virus characterization results) are summarized"/>
 <result pre="in Table 1. Table 1 Epidemiologic characteristics of the three" exact="influenza" post="seasons: number of samples tested, number of influenza viruses"/>
 <result pre="the three influenza seasons: number of samples tested, number of" exact="influenza" post="viruses detected and detailed virus characterization results. Season 2016/2017"/>
 <result pre="diversity and complexity in the pattern of the different circulating" exact="influenza" post="virus lineages, and genetic clades and subclades observed during"/>
 <result pre="sequencing during this season. Vaccine Effectiveness Generally, in Austria the" exact="influenza" post="vaccine coverage is traditionally very low and ranged during"/>
 <result pre="2 Number of cases and controls (vaccinated and unvaccinated) and" exact="influenza" post="vaccine effectiveness (IVE) adjusted for sex, age, and comorbidity"/>
 <result pre="QIV) and 2018/19 (C); n.d., not done; QIV, quadrivalent inactivated" exact="influenza" post="vaccines; CI, confidence interval. (A) Season 2016/17 Controls Cases"/>
 <result pre="(Table 1, Figure 2). Figure 2 Proportion (%) of circulating" exact="influenza" post="virus genetic subclades during seasons 2016/17 to 2018/19; Black:"/>
 <result pre="seasons 2016/17 to 2018/19; Black: IVE overall, blue: IVE against" exact="influenza" post="A(H3N2), red: IVE against influenza A(H1N1)pdm09, green: IVE against"/>
 <result pre="IVE overall, blue: IVE against influenza A(H3N2), red: IVE against" exact="influenza" post="A(H1N1)pdm09, green: IVE against Influenza B (aTIV/TIV/QIV and LAIV),"/>
 <result pre="the previous one in the following season 2017/18, dominated by" exact="influenza" post="B viruses with a co-circulation of A(H1N1)pdm09 strains, an"/>
 <result pre="of A(H1N1)pdm09 strains, an overall IVE of 39% [A(H1N1)pdm09 25%," exact="influenza" post="B 45%] was observed (Table 2B). This far from"/>
 <result pre="mismatch between TIV/aTIV vaccine strain (Victoria lineage) and the circulating" exact="influenza" post="B strains (Yamagata lineage; Figure 2). Despite the low"/>
 <result pre="Figure 2). Despite the low overall IVE and the pronounced" exact="influenza" post="B lineage mismatch of the TIV/aTIV vaccine strain a"/>
 <result pre="of the TIV/aTIV vaccine strain a quite good IVE against" exact="influenza" post="B viruses of 63% could be observed in children"/>
 <result pre="the diverse and complex pattern of the circulation of different" exact="influenza" post="virus lineages and genetic clades and subclades during a"/>
 <result pre="on the results of the genetic characterization of the circulating" exact="influenza" post="viruses during different time periods of epidemic influenza virus"/>
 <result pre="the circulating influenza viruses during different time periods of epidemic" exact="influenza" post="virus circulation (≥50% of samples influenza virus positive) and"/>
 <result pre="time periods of epidemic influenza virus circulation (≥50% of samples" exact="influenza" post="virus positive) and their influence on IVE estimates. Discussion"/>
 <result pre="by the Austrian sentinel surveillance system on the evolution of" exact="influenza" post="viruses during the seasons 2016/17 to 2018/19 and the"/>
 <result pre="2016/17 to 2018/19 and the impact of genetic drift on" exact="influenza" post="IVE. IVE estimates were carried out using the test-negative"/>
 <result pre="vaccinated persons have the same likelihood of being exposed to" exact="influenza" post="as non-vaccinated persons, and that vaccinated and unvaccinated have"/>
 <result pre="these two groups. The circulation of a heterogeneous mix of" exact="influenza" post="virus strains of different types, subtypes and genetic subclades"/>
 <result pre="the vaccine strains was typical for each of the three" exact="influenza" post="epidemics, substantially reducing IVE. The 2016/17 influenza season differed"/>
 <result pre="of the three influenza epidemics, substantially reducing IVE. The 2016/17" exact="influenza" post="season differed from the other two seasons by the"/>
 <result pre="other two seasons by the absolute dominance of one specific" exact="influenza" post="A subtype and its evolving subclades (Table 1, Figure"/>
 <result pre="rarely observed. Sequence analyses revealed substantial heterogeneity in the circulating" exact="influenza" post="viruses and showed the emergence of the A(H3N2) genetic"/>
 <result pre="viruses showed regional differences, depending on the start of the" exact="influenza" post="season in the different European regions. In the northern"/>
 <result pre="the northern parts of Europe, in Sweden and Finland, the" exact="influenza" post="season 2016/17 started early in weeks 47/2016 to 49/2016"/>
 <result pre="already in week 52/2016 (14). In these countries the genetic" exact="influenza" post="surveillance revealed the presence of the genetic A(H3N2) subclade"/>
 <result pre="is in contrast to that observed in Austria, where the" exact="influenza" post="season started several weeks later with its peak in"/>
 <result pre="peak in week 02/2017. The time dependent spread of the" exact="influenza" post="virus activity throughout Europe may explain the differences in"/>
 <result pre="Austria 3C.2a1 subclade accounted already for 71% of the circulating" exact="influenza" post="viruses at the beginning of the season. This may"/>
 <result pre="the season. This may also partly explain the absence of" exact="influenza" post="vaccine protection in Austria, where negative IVEs throughout the"/>
 <result pre="wide range of various patterns in the epidemiologic dominance of" exact="influenza" post="virus types and subtypes was observed in different parts"/>
 <result pre="While in the US A(H3N2) viruses dominated, a co-circulation of" exact="influenza" post="B/Yamagata and A(H3N2) viruses was observed in Canada (18)."/>
 <result pre="was observed in Canada (18). In Europe the majority of" exact="influenza" post="viruses detected were influenza viruses type B. But even"/>
 <result pre="(18). In Europe the majority of influenza viruses detected were" exact="influenza" post="viruses type B. But even in Europe the pattern"/>
 <result pre="strains differed locally. While in UK an equal co-circulation of" exact="influenza" post="B viruses and influenza A(H3N2) viruses was observed, in"/>
 <result pre="in UK an equal co-circulation of influenza B viruses and" exact="influenza" post="A(H3N2) viruses was observed, in continental Europe influenza B"/>
 <result pre="viruses and influenza A(H3N2) viruses was observed, in continental Europe" exact="influenza" post="B viruses dominated with locally different proportions of co-circulating"/>
 <result pre="different proportions of co-circulating A(H1N1)pdm09 and/or A(H3N2) viruses. In Austria" exact="influenza" post="B viruses accounted for 67% of the circulating viruses"/>
 <result pre="(4%). In Austria the observed type-specific IVE of 45% against" exact="influenza" post="B virus infections was comparable with international published data"/>
 <result pre="from 25 to 55% was reported (18–20). Despite the pronounced" exact="influenza" post="B lineage mismatch of the TIV/aTIV vaccine strain (vaccine"/>
 <result pre="strain B/Victoria), still a quite good IVE against the circulating" exact="influenza" post="B/Yamagata viruses was observed. This phenomenon can be explained"/>
 <result pre="B/Yamagata viruses was observed. This phenomenon can be explained by" exact="influenza" post="B lineage cross-protection, where birth-cohort effects induced by differential"/>
 <result pre="vaccinated with quadrivalent vaccines (QIV/LAIV, perfect vaccine match for the" exact="influenza" post="B/Yamagata component) an increased overall IVE of 46% and"/>
 <result pre="UK (19), which show no effectivity for the TIV against" exact="influenza" post="B, but excellent effectivity of the LAIV against influenza"/>
 <result pre="against influenza B, but excellent effectivity of the LAIV against" exact="influenza" post="B (61%) and A(H1N1)pdm09 (91%). In Austria A good"/>
 <result pre="including all kind of vaccines used (mostly TIV) revealed an" exact="influenza" post="A(H1N1)pdm09 specific IVE of only 25% for this season."/>
 <result pre="the following season 2018/19, as this season was dominated by" exact="influenza" post="A viruses. In Canada (22) and Hong Kong (23)"/>
 <result pre="viruses. In Canada (22) and Hong Kong (23) the 2018/19" exact="influenza" post="season was dominated by influenza A(H1N1)pdm09 viruses. In Europe"/>
 <result pre="Hong Kong (23) the 2018/19 influenza season was dominated by" exact="influenza" post="A(H1N1)pdm09 viruses. In Europe a complex and over the"/>
 <result pre="the season constantly changing pattern of the circulation of both" exact="influenza" post="A virus subtypes was observed. UK reported the co-circulation"/>
 <result pre="virus subtypes was observed. UK reported the co-circulation of both" exact="influenza" post="A virus subtypes, while counties on the European continent"/>
 <result pre="This significant differences in the geographic spread of the two" exact="influenza" post="A subtypes and their genetic subclades, may also explain"/>
 <result pre="subclades, may also explain differences in IVE estimates. In Austria" exact="influenza" post="A(H1N1)pdm09 viruses dominated during the season 2018/19 accounting for"/>
 <result pre="dominated during the season 2018/19 accounting for 2/3 of all" exact="influenza" post="virus infections. Notably, an increase in the proportion of"/>
 <result pre="virus infections. Notably, an increase in the proportion of circulating" exact="influenza" post="A(H3N2) viruses could be observed over time, with 24%"/>
 <result pre="and subclusters. Due to the general genetic variability of the" exact="influenza" post="viruses and their ability for reassortment, it is not"/>
 <result pre="by the close genetic monitoring carried out in the national" exact="influenza" post="surveillance (Table 1). In Austria, out of 90 viruses"/>
 <result pre="the temporal differences in their distribution. Hence, for the 2018/19" exact="influenza" post="season a broad range for the A(H3N2) specific IVE"/>
 <result pre="from between 46 and 92% (22–24). In addition to the" exact="influenza" post="virus genetic diversity, the degree of epidemic influenza virus"/>
 <result pre="to the influenza virus genetic diversity, the degree of epidemic" exact="influenza" post="virus circulation also effects IVE estimates. A higher level"/>
 <result pre="circulation also effects IVE estimates. A higher level of epidemic" exact="influenza" post="virus circulation is associated with higher exposure rates and"/>
 <result pre="lower IVE estimates in seasons with a high degree of" exact="influenza" post="virus activity. In contrast, higher IVE estimates may be"/>
 <result pre="may be observed in seasons with a low degree of" exact="influenza" post="virus activity. This may explain the relatively good vaccine"/>
 <result pre="strains are only possible for distinct time periods of an" exact="influenza" post="season and with an adjustment for the genetic pattern"/>
 <result pre="with an adjustment for the genetic pattern of the circulating" exact="influenza" post="viruses. Although, our data indicate a correlation between IVE"/>
 <result pre="relationship will require the further analysis of a few more" exact="influenza" post="seasons. IVE estimates are challenging and difficult, as they"/>
 <result pre="dynamic of the ever changing genetic pattern of the circulating" exact="influenza" post="viruses and their influence on IVE estimates. This genetic"/>
 <result pre="complicates the decisions of the WHO on suitable and optimal" exact="influenza" post="vaccine strains and underscores the importance of the development"/>
 <result pre="the importance of the development and availability of a universal" exact="influenza" post="vaccine. Data Availability Statement The datasets generated for this"/>
 <result pre="epidemiological data of fully anonymized material collected during the annual" exact="influenza" post="surveillance within the frame of Austria's Sentinel Physician Surveillance"/>
 <result pre="here for additional data file. References References 1.collab: WHOVaccines against" exact="influenza" post="WHO position paper - November 2012. Wkly Epidemiol Rec."/>
 <result pre="Integrated sentinel surveillance linking genetic, antigenic, and epidemiologic monitoring of" exact="influenza" post="vaccine-virus relatedness and effectiveness during the 2013-2014 influenza season."/>
 <result pre="monitoring of influenza vaccine-virus relatedness and effectiveness during the 2013-2014" exact="influenza" post="season. J Infect Dis. (2015) 212:726–39. 10.1093/infdis/jiv17725784728 5.RambhiaKJRambhiaMT. Early"/>
 <result pre="Infect Dis. (2019) 68:1235–40. 10.1093/cid/ciy74830169619 6.Redlberger-FritzMKundiMPopow-KrauppT. Detailed report on 2014/15" exact="influenza" post="virus characteristics, and estimates on influenza virus vaccine effectiveness"/>
 <result pre="Detailed report on 2014/15 influenza virus characteristics, and estimates on" exact="influenza" post="virus vaccine effectiveness from Austria‘s Sentinel Physician Surveillance Network."/>
 <result pre="Dynamics of antigenic and genetic changes in the hemagglutinins of" exact="influenza" post="A/H3N2 viruses of three consecutive seasons (2002/2003 to 2004/2005)"/>
 <result pre="Mol Biol Evol.24:1596–9.17488738 11.SavageRDWinterALRosellaLCOlshaRGubbayJBSkowronskiDMet al.. Strengths and limitations of assessing" exact="influenza" post="vaccine effectiveness using routinely collected, passive surveillance data in"/>
 <result pre="versus quality. Euro Surveill. (2015) 20:21100. 10.2807/1560-7917.ES2015.20.16.2110025953275 12.PebodyRWarburtonFEllisJAndrewsNPottsACottrellSet al.. End-of-season" exact="influenza" post="vaccine effectiveness in adults and children, United Kingdom, 2016/17."/>
 <result pre="13.SkowronskiDMChambersCSabaiducSDickinsonJAWinterALDe SerresGet al.. Interim estimates of 2016/17 vaccine effecteiveness against" exact="influenza" post="A(H3N2), Canada, January (2017). Euro Surveill. (2017) 22:30460. 10.2807/1560-7917.ES.2017.22.6.3046028205503"/>
 <result pre="(2017) 22:30460. 10.2807/1560-7917.ES.2017.22.6.3046028205503 14.HergensMPBaumUBryttingMIkonenNHaveriAWimanAet al.. Mid-season real-time estimates of seasonal" exact="influenza" post="vaccine effectiveness in persons 65 years and older in"/>
 <result pre="(2017) 22:30469. 10.2807/1560-7917.ES.2017.22.8.3046928251891 15.KisslingERondyM. Early 2016/17 vaccine effectiveness estimates against" exact="influenza" post="A(H3N2): I-MOVE multicentre case control studies at primary care"/>
 <result pre="10.2807/1560-7917.ES.2017.22.7.3046428230524 16.BelongiaEA. Beyond antigenic match: moving toward greater understanding of" exact="influenza" post="vaccine effectiveness. J Infect Dis. (2017) 216:1477–80. 10.1093/infdis/jix52729029175 17.SkowronskiDMChambersCDe"/>
 <result pre="(2019) 68:1754–7. 10.1093/cid/ciy87630312364 18.SkowronskiDMChambersCDe SerresGDickinsonJAWinterALHickmanRet al.. Early season co-circulation of" exact="influenza" post="A(H3N2) and B(Yamagata): interim estimates of 2017/18 vaccine effectiveness,"/>
 <result pre="Euro Surveill. (2018) 23:18-00035. 10.2807/1560-7917.ES.2018.23.5.18-0003529409570 19.PebodyRDjennadAEllisJAndrewsNMarquesDFPCottrellSet al.. End of season" exact="influenza" post="vaccine effectiveness in adults and children in the United"/>
 <result pre="2017/18. Euro Surveill. (2019) 24:1800488. 10.2807/1560-7917.ES.2019.24.31.180048831387673 20.RondyMKisslingEEmborgHDGherasimAPebodyRTrebbienRet al.. Interim 2017/18" exact="influenza" post="seasonal vaccine effectiveness: combined results from five European studies."/>
 <result pre="European studies. Euro Surveill. (2018) 23:18-00086. 10.2807/1560-7917.ES.2018.23.9.18-0008629510782 21.TriccoACChitASoobiahCHallettDMeierGChenMHet al.. Comparing" exact="influenza" post="vaccine efficacy against mismatched and matched strains: a systematic"/>
 <result pre="10.3138/CTR.153.00523800265 22.SkowronskiDMLeirSSabaiducSMurtiMDickinsonJAOlshaRet al.. Interim estimates of 2018/19 vaccine effectiveness against" exact="influenza" post="A(H1N1)pdm09, Canada, January (2019). Euro Surveill. (2019) 24:1900055. 10.2807/1560-7917.ES.2019.24.4.190005530696523"/>
 <result pre="Surveill. (2019) 24:1900055. 10.2807/1560-7917.ES.2019.24.4.190005530696523 23.ChiuSSKwanMYFengSChanELChuaHWongJSet al.. Early season estimate of" exact="influenza" post="vaccination effectiveness against influenza hospitalisation in children, Hong Kong,"/>
 <result pre="23.ChiuSSKwanMYFengSChanELChuaHWongJSet al.. Early season estimate of influenza vaccination effectiveness against" exact="influenza" post="hospitalisation in children, Hong Kong, winter influenza season 2018/19."/>
 <result pre="vaccination effectiveness against influenza hospitalisation in children, Hong Kong, winter" exact="influenza" post="season 2018/19. Euro Surveill. (2019) 24:1900056. 10.2807/1560-7917.ES.2019.24.5.190005630722814 24.KisslingERoseAEmborgHDGherasimAPebodyRPozoFet al.."/>
 <result pre="2018/19. Euro Surveill. (2019) 24:1900056. 10.2807/1560-7917.ES.2019.24.5.190005630722814 24.KisslingERoseAEmborgHDGherasimAPebodyRPozoFet al.. Interim 2018/19" exact="influenza" post="vaccine effectiveness: six European studies, October 2018 to January"/>
 <result pre="24:1900121. 10.2807/1560-7917.ES.2019.24.190012130808440 25.PebodyRAndrewsNMcMenaminJDurnallHEllisJThompsonCIet al.. Vaccine effectiveness of 2011/12 trivalent seasonal" exact="influenza" post="vaccine in preventing laboratory-confirmed influenza in primary care in"/>
 <result pre="effectiveness of 2011/12 trivalent seasonal influenza vaccine in preventing laboratory-confirmed" exact="influenza" post="in primary care in the United Kingdom: evidence of"/>
 <result pre="18:20389. 10.2807/ese.18.05.20389-en23399424 26.GherasimAMartinez-BazICastillaJPozoFLarrauriA. Effect of previous and current vaccination against" exact="influenza" post="A(H1N1)pdm09, A(H3N2), and B during the post-pandemic period 2010-2016"/>
 <result pre="al.. Beyond antigenic match: possible agent-host and immuno-epidemiological influences on" exact="influenza" post="vaccine effectiveness during the 2015-2016 season in Canada. J"/>
 <result pre="J Infect Dis. (2017) 216:1487–500. 10.1093/infdis/jix52629029166 28.FonvilleJMWilksSHJamesSLFoxAVentrescaMAbanMet al.Antibody landscapes after" exact="influenza" post="virus infection or vaccination. Science. (2014) 346:996–1000. 10.1126/science.125642725414313"/>
</results>
